Deep search
Profile Picture
  • All
  • Search
  • Copilot
  • Images
  • Videos
  • Maps
  • News
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Past 7 days
    • Any time
    • Past hour
    • Past 24 hours
    • Past 30 days

News

The Lancet4d
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Copyright: © 2015 Elsevier Ltd. Published by Elsevier Ltd.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now

Buys back first six albums
Lets revoke parole program
Tariffs back on for now
Jailed for selling daughter
Feds probe impersonator
Deaf Americans sue Trump
Prosecution rests its case
Unveils new supercomputer
DOJ cuts ABA judicial vetting
National Spelling Bee winner
ICE leadership overhaul
Canada wildfires spread
Ex-NYPD commissioner dies
Signs AI deal with Amazon
Brand pleads not guilty
Paul Ingrassia to lead OSC
SCOTUS narrows NEPA
Garcia eyes Oversight role
Sale reaches 2,500 strikeouts
US govt. employee charged
On US-China trade talks
Nigeria floods
US inflation gauge cools
US scholar leaves Thailand
Ex-banker sentenced
Beef stew recall
MLB announces investment
Sued over wrongful arrests?
Mondelez sues Aldi
US trade deficit narrows
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy